Obsessive compulsive disorder. Obsessive-compulsive disorder
Conditions
Interventions
Intervention 1: Intervention group: The intervention group is a group of 20 people who will receive ondansetron by a medical assistant. This medication belongs to the class of serotonin 5-HT3 receptor
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Diagnosis of obsessive-compulsive disorder based on the Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition Age range: 18 to 50 years Total score of the Yale-Brown Obsessive Compulsive Scale above 16 Ventricular electrical(QT)interval less than 420 milliseconds on ECG prior to the start of the study No history of prolonged ventricular electrical interval syndrome in the patient or their family
Exclusion criteria
Exclusion criteria: Active phase of psychotic disorders such as schizophrenia and major depression Concurrent serious medical illness including hepatic, renal, and electrolyte problems (any abnormal paraclinical findings in serum urea,creatinin,liver function test,blood chemistry) Cardiac problems in the individual (including structural, conduction, or vascular disorders) or a family history of cardiac conduction disorders Structural brain disease Alcohol and substance use Intellectual disability Pregnancy and breastfeeding period Undergoing any form of psychotherapy at present
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Obsessive Compulsive Disorder symptom severity based on the Yale-Brown Obsessive Compulsive Scale. Timepoint: Before the intervention, 8 weeks and 12 weeks after the start of the intervention. Method of measurement: Yale-Brown Obsessive Compulsive Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Response to treatment(more than 35% reduction in Yale-Brown Obsessive Compulsive Scale ). Timepoint: Before the intervention, 8 weeks and 12 weeks after the start of the intervention. Method of measurement: Yale-Brown Obsessive Compulsive Scale.;Safety of ondansetron. Timepoint: Before the intervention, 8 weeks and 12 weeks after the start of the intervention. Method of measurement: Clinical interview.;Tolerability of ondansetron (QT interval changes). Timepoint: Before the intervention, 8 weeks and 12 weeks after the start of the intervention. Method of measurement: Electerocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNadia Vakili Sadeghi
Rasht University of Medical Sciences
Outcome results
None listed